Bacil Pharma Limited (BACPHAR.BO)
INR 60.12
(-1.99%)
INR 60.12
(-1.99%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -513 Thousand | -1.47 Million | -40.08 Million | -3.98 Million | -3.78 Million | -2.99 Million |
| Net Income | -591 Thousand | -1.01 Million | -38.6 Million | -2.39 Million | -3.15 Million | -3.43 Million |
| Depreciation & Amortization | 20 Thousand | 26.92 Thousand | 37.17 Thousand | 49.31 Thousand | 82.24 Thousand | 91 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 57 Thousand | -188.41 Thousand | -950.7 Thousand | -215 Thousand | 709.1 Thousand | 1.28 Million |
| Other non-cash items | 9000.00 | -294.44 Thousand | -575.68 Thousand | -1.41 Million | -1.41 Million | -941 Thousand |
| Investing Cash Flow | 490 Thousand | -1.16 Million | 38.12 Million | 5.27 Million | 3.86 Million | 2.79 Million |
| Investments in PPE | - | - | - | - | - | -38.45 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | -1.45 Million | - | - | - | - |
| Sales/Maturities of investments | 489 Thousand | - | 37.54 Million | 3.85 Million | 2.45 Million | 1.92 Million |
| Other Investing Activities | 1000.00 | 294.44 Thousand | 575.68 Thousand | 1.41 Million | 1.41 Million | 915.18 Thousand |
| Financing Cash Flow | 150 Thousand | 627.63 Thousand | 3.27 Million | -733.08 Thousand | -555.56 Thousand | -1.64 Million |
| Debt repayment | -150 Thousand | -502.63 Thousand | -1.84 Million | -665.02 Thousand | -738.23 Thousand | -950 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | 1.13 Million | 5.12 Million | -68.06 Thousand | 182.67 Thousand | -699.61 Thousand |
| Accounts receivables | - | - | - | - | - | 109.96 Thousand |
| Accounts payables | 32 Thousand | -103.01 Thousand | -4402.00 | -242.57 Thousand | 983.61 | 311.08 Thousand |
| Inventory | - | - | - | - | - | 950 Thousand |
| Other working capital | 25 Thousand | -85.4 Thousand | -946.3 Thousand | 27.57 Thousand | 708.11 Thousand | -82.81 Thousand |
| Cash at beginning of period | 287.82 Thousand | 2.29 Million | 990.65 Thousand | 425.84 Thousand | 895.35 Thousand | 2.74 Million |
| Cash at end of period | 415 Thousand | 287.82 Thousand | 2.29 Million | 990.36 Thousand | 425.84 Thousand | 895.16 Thousand |
| Capital Expenditure | - | - | - | - | - | -38.45 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 127.17 Thousand | -2 Million | 1.3 Million | 564.51 Thousand | -469.51 Thousand | -1.84 Million |
| Free Cash Flow | -513 Thousand | -1.47 Million | -40.08 Million | -3.98 Million | -3.78 Million | -3.03 Million |
| Breakdown | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -591 Thousand | -244 Thousand | -115 Thousand | 174 Thousand | -1.01 Million | -761 Thousand |
| Depreciation & Amortization | 20 Thousand | 5000.00 | 5000.00 | 5000.00 | 26.92 Thousand | 6000.00 |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 57 Thousand | - | - | - | -188.41 Thousand | - |
| Other non-cash items | 9000.00 | 249 Thousand | -5000.00 | -5000.00 | -294.44 Thousand | -6000.00 |
| Investing Cash Flow | 490 Thousand | - | - | - | -1.16 Million | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | -1.45 Million | - |
| Sales/Maturities of investments | 489 Thousand | - | - | - | - | - |
| Other Investing Activities | 1000.00 | - | - | - | 294.44 Thousand | - |
| Financing Cash Flow | 150 Thousand | - | - | - | 627.63 Thousand | - |
| Debt repayment | -150 Thousand | - | - | - | -502.63 Thousand | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | 1.13 Million | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 32 Thousand | - | - | - | -103.01 Thousand | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 25 Thousand | - | - | - | -85.4 Thousand | - |
| Cash at beginning of period | 287.82 Thousand | 273 Thousand | 388 Thousand | 287.82 Thousand | 2.29 Million | 1.04 Million |
| Cash at end of period | 415 Thousand | 283 Thousand | 273 Thousand | 174 Thousand | 287.82 Thousand | 287.82 Thousand |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 127.17 Thousand | 10 Thousand | -115 Thousand | -113.82 Thousand | -2 Million | -761 Thousand |
| Free Cash Flow | -513 Thousand | 10 Thousand | -115 Thousand | 174 Thousand | -1.47 Million | -761 Thousand |
GDI
BEKAY
ZYDUSLIFE
2420
UNIVCABLES
HGGCF